OOIR: Observatory of International Research

Papers

(The H4-Index of Lancet Respiratory Medicine is 77. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Savolitinib in NSCLC: progress in the MET exon 14 journey	548
Broad protection from SARS-CoV-2 variants without antigen matching	339
European Respiratory Society International Congress 2022	286
European Society of Intensive Care Medicine (ESICM) LIVES 35th Annual Congress	273
Predatory publishers appear in PubMed (and your inbox)	260
Opioids bring peace to patients with IPF cough	260
Thoracentesis: an old story and some new sources	255
Chronic obstructive pulmonary disease: 10 years of precision-guided success	230
Correction to Lancet Respir Med 2024; 12: 129–40	226
Interstitial lung disease: a decade of progress and hope	219
The burden of tuberculosis in Libya	216
Rituximab for connective tissue disease-associated interstitial lung disease	212
Rethinking the role of procalcitonin in suspected sepsis	211
Major gaps in childhood pneumonia research priorities remain	209
US Senate committee investigates asthma inhaler prices	204
Video laryngoscopy is not the nemesis of direct laryngoscopy	200
Predicted bodyweight—a misleading metric for tidal volume titration?	194
Chronic respiratory diseases in Asia: time for action	193
Optimising trial design for cardiogenic shock: insights from the sixth Critical Care Clinical Trialists Workshop	192
Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis	192
Concerns regarding a suggested long COVID paradigm – Authors' reply	191
Impact of Myanmar's earthquake on respiratory health	187
Top ten research priorities for breathlessness research: UK James Lind Alliance priority setting partnership	184
Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study	180
First results from the international paediatric bronchiectasis registry (Child-BEAR-Net Registry) describing multicountry variations in childhood bronchiectasis and its management: a multicentre, cros	176

FLiRTing with danger as SARS-CoV-2 variants evolve	171
Rheumatoid arthritis-associated interstitial lung disease: screening, diagnosis, and treatment—an expert group consensus statement	169
Long COVID: systemic inflammation and obesity as therapeutic targets	169
Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis	168
Australia bans engineered stone to prevent silicosis	151
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial	143
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials	143
Challenges of modulating the risk of bronchopulmonary dysplasia in clinical trials	142
Overcoming barriers to scaling up tuberculosis preventive treatment for household contacts	140
Health effects of gas fuels: interpreting evidence from a comprehensive meta-analysis	137
Sarcoidosis and fatigue: there is a useful cognitive treatment? – Authors' reply	136
Claudio Castanos—leader in cystic fibrosis care in Argentina	136
Nasally delivered SARS-CoV-2 vaccines: future promise and challenges	133
Solid and semi-solid perspectives in thoracic surgery	131
Genetic associations and lung function in IPF: unexpected answers, persistent questions	127
Patient with cystic fibrosis not diagnosed until age 23 years now treated with the new triple therapy Trikafta	127
Extracorporeal cardiopulmonary resuscitation: not why, but how	126
Endotracheal surfactant for infants with life-threatening bronchiolitis (BESS): a randomised, blinded, sham-controlled, phase 2 trial	121
Trump administration decimates worker health oversight	121
Correction to Lancet Respir Med 2022; 10: 972–84	120
Correction to Lancet Respir Med 2021; 9: 1275–87	120
Correction to Lancet Respir Med 2025; 13: 244–55	119
Non-invasive respiratory supports and criteria for intubation in randomised trials of acute hypoxaemic respiratory failure: a systematic review and network meta-analysis	117
Precision-guided immunomodulatory therapy in sepsis	114
Sphaerosymphony: turning air quality data into music	114
Association of SARS-CoV-2 infection and persistence with long COVID	112
Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial	111
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, m	111
Evaluation of the effect of multimorbidity on difficult-to-treat asthma using a novel score (MiDAS): a multinational study of asthma cohorts	110
Transbronchial cryobiopsy followed by as-needed surgical lung biopsy versus immediate surgical lung biopsy for diagnosing interstitial lung disease (the COLD study): a randomised controlled trial	110
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CRO	108
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, doub	106
Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study	106
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis	103
Preoxygenation strategies for intubation of patients who are critically ill: a systematic review and network meta-analysis of randomised trials	102
Effectiveness of preventive treatment among different age groups and Mycobacterium tuberculosis infection status: a systematic review and individual-participant data meta-analysis of contact tracing s	102
Chronic cough as a disease: implications for practice, research, and health care	102
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, co	98
Health effects from climate-driven events: lessons learnt	97
Perioperative lung expansion and pulmonary outcomes after open abdominal surgery versus usual care in the USA (PRIME-AIR): a multicentre, randomised, controlled, phase 3 trial	97
Spirometry in female individuals – Authors' reply	96
Choice overload for RSV prevention—how to form your opinion	95
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration	95
Developments and priorities in bronchiectasis research	93
The Ramp to Nowhere: When hope slips through the cracks in care	93
US lung cancer report suggests years of encouraging progress under threat from health agency cuts	93
Management after combined BPA and medical therapy in CTEPH: time for cardiopulmonary exercise testing	92
NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma	91
Determinants of long-term outcomes in patients with COVID-19 supported with ECMO	83
COP27 Climate Change Conference: urgent action needed for Africa and the world	79

Underappreciated causes of obstructive lung disease	78
Liberal or restrictive transfusion for VV ECMO	77